Sir Gregory Winter, CBE, FRS
Sir Gregory Winter is a member of the Medical Research Council’s Laboratory of Molecular Biology (LMB) in Cambridge and a Fellow of Trinity College, Cambridge. He has served LMB as a Head of Division, Deputy Director, and Acting Director. His scientific career has been based almost entirely in Cambridge, where his work has included protein and nucleic acid sequencing. He later developed technologies for making humanized antibodies (by grafting hypervariable regions from rodent antibodies to human antibodies) and also for making synthesizing human antibodies in bacteria (using antibody repertories and phage display technologies). Most of the therapeutic antibodies on the market have been developed using methods that have been devised by him. He was a Founder and Director of Cambridge Antibody Technology (acquired by AstraZeneca), a Founder and Director of Domantis (acquired by GSK), and more recently, a Founder and Director of Bicycle Therapeutics. Sir Gregory has received several major international prizes, including the King Faisal Prize for Medicine and the Louis-Jeantet Prize for Medicine. In 2004, he was knighted for services to Molecular Biology.
Cori Gorman, PhD, MBA
Dr. Cori Gorman brings an outstanding record of achievement in basic research and drug development applications in diverse areas, including gene therapy, gene expression and transfer, hormone processing, cell biology, protein transport, and the humanization and production of recombination of proteins. Her strong publication record has resulted in over 13,000 citations and 6 classic citations. Dr. Gorman developed the CAT assay in 1980 as a post doctoral fellow in the LMB/NCI. This assay was developed as a sensitive measure of gene expression and was the industry standard for over 15 years. At Genentech, Dr. Gorman played a key role in the development of a number of marketed products, including Kogenate, Activase, Herceptin, Xolair, and Raptiva. Dr. Gorman also played a role in the early stages of Avastin. Based on her work at Genentech, Dr. Cori Gorman is recognized as a pioneer in the development of monoclonal antibody therapeutics and has coauthored 6 INDs. Upon leaving her position at Genentech, she cofounded two biotech startups, one of which, Valentis, a gene therapy company, has gone public.
Dr. Gorman has received several fellowships from such organizations as the American Cancer Society, the National Cancer Institute, the European Molecular Biology Organization, and NATO.
Professor Nicolas Mermod, PhD
Nicolas Mermod is Professor of Biotechnology at the Faculty of Biology and Medicine of the University of Lausanne. After completing his doctoral studies at the University of Geneva and his post doctoral studies at the University of California, Berkeley, USA, Professor Mermod joined the University of Lausanne as an Assistant Professor of the Swiss National Science Foundation and became Full Professor in the Department of Biotechnology. He is also a cofounder and board member of Selexis. As head of a laboratory with over 20 scientists, Professor Mermod conducts teaching and research activities at the Center for Biotechnology UNIL-EPFL. Professor Mermod has gained a reputation in the fields of molecular biology and the control of gene expression and has authored a number of scientific publications and patents.